Nelson Sun Sells 62,000 Shares of Aardvark Therapeutics (NASDAQ:AARD) Stock

Aardvark Therapeutics, Inc. (NASDAQ:AARD) insider Nelson Sun sold 62,000 shares of the business’s stock in a transaction on Friday, September 11th. The shares were sold at an average price of $5.18, for a total transaction of $321,160.00. Following the sale, the insider owned 35,475 shares of the company’s stock, valued at $183,760.50. This trade represents a 63.61% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link.

Nelson Sun also recently made the following trade(s):

• On Thursday, September 10th, Nelson Sun sold 14,754 shares of Aardvark Therapeutics stock. The stock was sold at an average price of $5.00, for a total transaction of $73,770.00.

Aardvark Therapeutics Trading Up 2.4%

Aardvark Therapeutics stock opened at $5.13 on Friday. The firm has a market capitalization of $112.24 million, a price-to-earnings ratio of -1.60 and a beta of 3.74. The firm’s fifty day moving average price is $6.29 and its two-hundred day moving average price is $5.53. Aardvark Therapeutics, Inc. has a 1-year low of $3.35 and a 1-year high of $17.94.

Aardvark Therapeutics (NASDAQ:AARD) last posted its earnings results on Tuesday, August 11th. The company reported ($0.66) EPS for the quarter, topping the consensus estimate of ($0.87) by $0.21. On average, research analysts forecast that Aardvark Therapeutics, Inc. will post -3.17 EPS for the current year.

Aardvark Therapeutics News Roundup

Here are the key news stories impacting Aardvark Therapeutics this week:

• Positive Sentiment: No company-specific clinical, regulatory, or financial improvement was reported in the latest updates. The absence of new adverse operating news may limit additional selling pressure.
• Neutral Sentiment: Several law firms—including Hagens Berman, Rosen Law Firm, SBS Law, Pomerantz, Faruqi & Faruqi, and Bernstein Liebhard—are soliciting investors to seek lead-plaintiff status by October 13, 2026. These announcements largely repeat the same underlying lawsuit rather than representing separate cases. Hagens Berman investor notice
• Neutral Sentiment: A reported September short-interest update showed zero shares sold short, but the figures appear incomplete or unreliable because the reported change was listed as “NaN.” It therefore provides little useful insight into trading direction.
• Negative Sentiment: The securities class action covers investors who bought Aardvark shares in or traceable to the February 2025 IPO, or who purchased securities between February 13, 2025, and May 14, 2026. The litigation alleges violations of federal securities laws by the company and certain officers and directors. Pomerantz class-action announcement
• Negative Sentiment: One investor notice alleges that IPO materials described Aardvark’s ARD-101 drug candidate as 99% restricted to the gut and reported no serious adverse events, while allegedly omitting safety risks that later led to an FDA clinical hold. These remain allegations, but the claims create potential legal costs, uncertainty, and reputational damage. AARD shareholder alert

Wall Street Analyst Weigh In

AARD has been the topic of a number of recent research reports. HC Wainwright restated a “neutral” rating and issued a $6.00 target price on shares of Aardvark Therapeutics in a report on Monday, July 20th. Wall Street Zen upgraded Aardvark Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th. Finally, Weiss Ratings raised Aardvark Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 2nd. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Aardvark Therapeutics currently has a consensus rating of “Hold” and an average target price of $15.33.

Institutional Investors Weigh In On Aardvark Therapeutics

Several large investors have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Aardvark Therapeutics during the 2nd quarter worth $42,000. Persistent Asset Partners Ltd bought a new position in Aardvark Therapeutics during the fourth quarter valued at about $56,000. New York State Common Retirement Fund purchased a new stake in Aardvark Therapeutics during the second quarter worth about $99,000. MetLife Investment Management LLC bought a new stake in Aardvark Therapeutics in the fourth quarter worth about $102,000. Finally, Bank of America Corp DE raised its position in Aardvark Therapeutics by 72.9% in the second quarter. Bank of America Corp DE now owns 7,989 shares of the company’s stock worth $108,000 after acquiring an additional 3,369 shares during the period.

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.